PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Has Average Target Price of $25.25 According to Brokerages

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report) have been given an average rating of “Hold” by the sixteen research firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.25.

Several equities research analysts recently weighed in on the stock. Oppenheimer reiterated a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, September 9th. Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. TD Cowen reduced their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. UBS Group boosted their price target on shares of PROCEPT BioRobotics from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, October 15th.

Get Our Latest Stock Analysis on PROCEPT BioRobotics

PROCEPT BioRobotics Stock Performance

Shares of PRCT stock opened at $23.80 on Monday. The firm has a market capitalization of $1.37 billion, a P/E ratio of -11.78 and a beta of 0.88. PROCEPT BioRobotics has a 1 year low of $16.67 and a 1 year high of $38.11. The firm’s fifty day simple moving average is $19.52 and its 200 day simple moving average is $22.95. The company has a current ratio of 5.89, a quick ratio of 4.73 and a debt-to-equity ratio of 0.16.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). The company had revenue of $98.29 million during the quarter, compared to the consensus estimate of $100.52 million. PROCEPT BioRobotics had a negative net margin of 32.60% and a negative return on equity of 33.23%. PROCEPT BioRobotics’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company earned ($0.38) earnings per share. As a group, sell-side analysts predict that PROCEPT BioRobotics will post -1.74 EPS for the current year.

Insider Buying and Selling

In other PROCEPT BioRobotics news, insider Pooja Sharma sold 4,710 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $19.71, for a total transaction of $92,834.10. Following the sale, the insider directly owned 106,471 shares of the company’s stock, valued at approximately $2,098,543.41. The trade was a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,753 shares of company stock worth $114,685 in the last three months. 4.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Entropy Technologies LP lifted its holdings in shares of PROCEPT BioRobotics by 91.1% during the third quarter. Entropy Technologies LP now owns 52,696 shares of the company’s stock valued at $960,000 after acquiring an additional 25,121 shares during the period. Advisors Asset Management Inc. acquired a new stake in shares of PROCEPT BioRobotics during the 3rd quarter worth about $360,000. Aberdeen Group plc lifted its holdings in PROCEPT BioRobotics by 88.2% during the 3rd quarter. Aberdeen Group plc now owns 125,700 shares of the company’s stock valued at $2,290,000 after purchasing an additional 58,893 shares during the last quarter. Fifth Third Bancorp boosted its position in PROCEPT BioRobotics by 71.9% in the third quarter. Fifth Third Bancorp now owns 161,139 shares of the company’s stock valued at $2,936,000 after buying an additional 67,420 shares in the last quarter. Finally, Fulcrum Asset Management LLP grew its stake in PROCEPT BioRobotics by 19,930.2% during the third quarter. Fulcrum Asset Management LLP now owns 21,232 shares of the company’s stock worth $387,000 after buying an additional 21,126 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company’s core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.

Featured Stories

Analyst Recommendations for PROCEPT BioRobotics (NASDAQ:PRCT)

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.